MRNA - Moderna, Inc.

If You Invested $2,500 in Moderna in 2019, This Is How Much You Would Have Today

You'd have a lot more money, but only if you resisted the temptation to take the initial profits.

Moderna says looking for opportunities in China after registering legal entity

BEIJING (Reuters) -Vaccine maker Moderna Inc said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. biotech firm registered a unit called Moderna (China) Biotech Ltd in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna's mRNA platform to the people of China," a company spokesperson said in response to a query from Reuters.

Possible Bearish Signals With Moderna Insiders Disposing Stock \

The fact that multiple Moderna, Inc. ( NASDAQ:MRNA ) insiders offloaded a considerable amount of shares over the past...

Moderna shares react to Covid resurgence news in China

Yahoo Finance Live discusses a drop in shares of Moderna after a report of a resurgence of Covid in China.

Is Moderna Stock a Buy Now?

Biotech giant Moderna (NASDAQ: MRNA) made a name for itself in the past couple of years as it developed and marketed one of the most successful coronavirus vaccines. Demand for coronavirus vaccines has started to fall, affecting Moderna's revenue. Is Moderna's stock worth considering, especially at current levels?

Is Trending Stock Moderna, Inc. (MRNA) a Buy Now?

Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

• 
  Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

  Zacks
• 
  Morgan Stanley (MS) Is a Trending Stock: Facts to Know Before Betting on It

  Zacks

3 Stocks You'll Be Glad You Bought at These Prices

The good news is you really don't have to -- and you still can win in the stock market. The success of Moderna's (NASDAQ: MRNA) blockbuster coronavirus vaccine helped the stock soar earlier in the pandemic. Here's why they shouldn't: The vaccine represents just the beginning of Moderna's growth story.

Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy

Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.

Biotech Stocks Are Already Risky -- Now There Are 3 New Headwinds to Face in 2023

Biotech investors love to take on oodles of risk in hopes of getting an outsized reward when one of their bets finally pays off. While NHPs account for only 0.5% of the animal models used in biomedicine, biotechs and other researchers in the U.S. have faced a shortage of NHPs since at least 2019.

Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%

Moderna (NASDAQ: MRNA) surprised investors last quarter when it didn't incur a loss despite a significant drop in sales. For the first three months of 2023, Moderna's revenue totaled just under $1.9 billion, which is just a fraction of the $6.1 billion it reported in the same period last year. Meanwhile, its operating expenses, totaling $2.2 billion, rose by more than 21%.

3 Magnificent Growth Stocks to Buy to Help Build a Millionaire Portfolio

It's never too early to start building a portfolio that may eventually make you a millionaire. Today, many growth stocks are suffering, but in some cases, prospects over time remain bright. Amazon (NASDAQ: AMZN) was on an earnings roll, delivering gains in net income year after year -- until last year, when the company swung to a loss for the first time since 2014.

Ready to Buy the Dip? This Biotech Stock Is a Smart Buy

Moderna (NASDAQ: MRNA) saw its shares jump in 2021 and 2022 on the back of strong sales of its COVID-19 vaccine Spikevax. Spikevax helped prove to the world the effectiveness of messenger RNA (mRNA) technology. The company advanced three COVID-19 vaccines from phase 1 to commercial status in a year.

Could Latecomer Moderna Match Big Pharma Rivals in RSV?

Moderna (NASDAQ: MRNA) started its billion-dollar story with the coronavirus vaccine. The company plans to submit its candidate for use in older adults to regulators soon and aims for a 2024 launch. The U.S. Food and Drug Administration (FDA) recently approved GSK's vaccine -- the first RSV vaccine to ever win a nod.

An Intrinsic Calculation For Moderna, Inc. (NASDAQ:MRNA) Suggests It's 46% Undervalued

Key Insights The projected fair value for Moderna is US$241 based on 2 Stage Free Cash Flow to Equity Moderna is...

Up 40% in 1 Day, Is Novavax Stock a Buy Now?

On May 9, Novavax (NASDAQ: NVAX) shareholders got a much-needed reprieve from the stock's downward trajectory over the last year. Novavax's decline is a regrettable one. Its coronavirus vaccine candidate ran into regulatory issues during clinical development, and arrived on the market much later than those of competitors like Pfizer and Moderna.

Down 49% and 71%! 2 Nasdaq stocks to buy today

Ben McPoland considers potential opportunities thrown up by the sell-off in growth shares. Here are two US stocks to buy while they're down. The post Down 49% and 71%! 2 Nasdaq stocks to buy today appeared first on The Motley Fool UK.

Is It Too Late to Buy Moderna Stock?

Demand for Moderna's (NASDAQ: MRNA) one and only product is on the decline. As we approach a post-pandemic situation, Moderna already has started to feel the impact. Does today's drop in vaccine sales mean it's too late to buy Moderna stock?

Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

Novavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the coronavirus vaccine race. To make matters worse, earlier this year, Novavax even questioned its ability to continue operations. Jacobs revealed details about his strategy to cut costs, manage cash flow, and match Novavax's size to the demand for its only product: the coronavirus vaccine.

3 Healthcare Stocks to Buy and Hold for the Next 10 Years

It's always a great idea to buy stocks and hold them for the long term. That means at least five years. This offers you the opportunity to benefit from any dividend payments and/or growth in earnings.

The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

High demand for coronavirus vaccines earlier in the pandemic pushed Moderna's (NASDAQ: MRNA) earnings into the stratosphere. In fact, Moderna could continue to generate billions in revenues annually from its first -- and so far, only -- approved product. For example, Moderna sold its vaccine to the U.S. government for about $26 a dose.

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

• 
  AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

  Zacks
• 
  Morgan Stanley (MS) Is a Trending Stock: Facts to Know Before Betting on It

  Zacks

Is Moderna a Value Stock to Buy Right Now?

Moderna (NASDAQ: MRNA) can be described in several ways. One description of Moderna you probably won't hear very often, however, is value stock. There is an argument to be made that Moderna is a value stock.

Moderna (NASDAQ:MRNA) climbs 3.1% this week, taking three-year gains to 131%

It hasn't been the best quarter for Moderna, Inc. ( NASDAQ:MRNA ) shareholders, since the share price has fallen 21% in...

Is Moderna Building a Respiratory Vaccine Empire?

Moderna (NASDAQ: MRNA) made a name for itself through its coronavirus vaccine. The vaccine has generated billions of dollars in earnings over the past two years. Now, however, demand from that star product is on the decline -- and Moderna faces a serious drop in revenue.